|
12 Feb 2008 |
Phase III program for AVE0010/ZP10 licensed from Zealand Pharma A/S will begin in the first quarter of 2008
|
|
12 Feb 2008 |
Compugen Announces In-Vivo Results for Two Novel Peptide Agonists of MAS GPCR for Potential Treatment of Cardiovascular Pathologies
|
|
12 Feb 2008 |
Valeant Pharmaceuticals reports positive Phase III results for retigabine in RESTORE 1
|
|
12 Feb 2008 |
Bentley Pharmaceuticals Announces Completion of Treatment in Phase II India Clinical Study in Type 2 Diabetes and Preliminary Clinical Results
|
|
11 Feb 2008 |
Unigene Initiates Phase I/II Clinical Study for Oral Calcitonin
|
|
11 Feb 2008 |
SciClone and Sigma-Tau Report Promising Interim Results From Phase 3 Hepatitis C Trial
|
|
07 Feb 2008 |
Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP
|
|
07 Feb 2008 |
Tornier And BioSET Enter Synthetic Growth Factor Pact
|
|
06 Feb 2008 |
Neose Receives Milestone Payment from Novo Nordisk on Factor VIII Program
|
|
05 Feb 2008 |
Althea Technologies Chosen by Quintessence Biosciences to Produce Lead Protein Oncology Drug
|
|
04 Feb 2008 |
AIM Therapeutics Advances Asthma Therapeutics Program
|
|
04 Feb 2008 |
IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
|
|
04 Feb 2008 |
ATryn(R) Meets Primary Endpoint
|
|
31 Jan 2008 |
FDA Accepts for Filing a Biologic License Application (BLA) for Dysport(R) in Cervical Dystonia
|
|
31 Jan 2008 |
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
|
|
30 Jan 2008 |
Lev Pharmaceuticals Receives Complete Response Letter for Cinryze(TM)
|
|
29 Jan 2008 |
Compugen Announces In-Vivo Results for Two Peptide Anti-Inflammatory and Cardio-Protective Drug Candidates
|
|
29 Jan 2008 |
Neose Announces Discontinuation of NE-180 Program
|
|
29 Jan 2008 |
Mentor Announces Completion of Subject Enrollment into Phase IIIb Pivotal Trial for Botulinum Toxin Type A
|
|
28 Jan 2008 |
Orthologic Announces FDA Acceptance of AZX100 IND Application in Dermal/Hypertrophic Scarring; Phase 1 Human Clinical Trial to Begin 1Q2008
|
|
28 Jan 2008 |
NPS Pharmaceuticals Provides Update on GATTEX(TM) Clinical Development in Short Bowel Syndrome
|
|
25 Jan 2008 |
Preclinical studies on pulmonary arterial hypertension – Proteo cooperates with Stanford University, USA
|
|
24 Jan 2008 |
Cangene's recombinant human growth hormone approved by the U.S. Food and Drug Administration
|
|
24 Jan 2008 |
Nuvelo Announces Results from Phase 3 NAPA Program in Acute Peripheral Arterial Occlusion
|
|
24 Jan 2008 |
Takeda Doses First Patient in A U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
|
